A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of DVS-233 SR [desvenlafaxine] for prevention of depressive relapse in adult outpatients with major depressive disorder.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of DVS-233 SR [desvenlafaxine] for prevention of depressive relapse in adult outpatients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2012

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Oct 2012 Primary endpoint 'Time-to-relapse' has been met.
    • 01 Feb 2010 Results published in the Journal of Clinical Psychopharmacology.
    • 25 Aug 2009 Actual patient number (603) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top